VEGFA and prostate carcinoma: Recent studies highlight the duality of the receptor in prostate cancer, demonstrating its prometastatic and proliferative effects through mechanisms involving the exosome/microvesicle, miRNA, and hypoxia-inducible factor-1 alpha (HIF-1α), which promote invasiveness and angiogenesis by elevating vascular endothelial growth factor (VEGF) levels [55,56].